Efficacy & Safety
Factor VIII Activity
Kovaltry Factor VIII activity
Compared to other SHL, Kovaltry, gives your patients more coverage over a typical week with 2x-weekly or 3x-weekly dosing
Kovaltry vs rAHF-PFM: typical 2x-weekly dosing1
Based on a head-to-head study comparing the pharmacokinetic profiles of Kovaltry vs. rAHF-PFM
All data were derived from a popPK-based simulation of a typical steady-state profile of a switch from 30 IU/kg rAHF-PFM to 30 IU/kg Kovaltry 2x-weekly or 3x-weekly. The popPK model provided an accurate description of chromogenic assay data (n=18).1
Adapted from Shah et al. 2017
*Example patient only for illustrative purposes. PopPK, population PK; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.
Kovaltry vs rAHF-PFM: typical 3x-weekly dosing1
All data were derived from a popPK-based simulation of a typical steady-state profile of a switch from 30 IU/kg rAHF-PFM to 30 IU/kg Kovaltry 2x-weekly or 3x-weekly. The popPK model provided an accurate description of chromogenic assay data (n=18).1
Adapted from Shah et al. 2017
*Example patient only for illustrative purposes. PopPK, population PK; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.
Recommendations
References
- Shah A, Solms A, Garmann D. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clin Pharmacokinet. 2017;56(9):1045-1055. Return to content
